Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma

Autologous stem cell transplantation (ASCT) can be curative for patients with relapsed/refractory Hodgkin lymphoma (HL). Based on studies suggesting that anti-PD-1 monoclonal antibodies (mAbs) can sensitize patients to subsequent chemotherapy, we hypothesized that anti-PD-1 therapy before ASCT would...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Blood Adv
Asıl Yazarlar: Merryman, Reid W., Redd, Robert A., Nishihori, Taiga, Chavez, Julio, Nieto, Yago, Darrah, Justin M., Rao, Uttam, Byrne, Michael T., Bond, David A., Maddocks, Kami J., Spinner, Michael A., Advani, Ranjana H., Ballard, Hatcher J., Svoboda, Jakub, Singh, Anurag K., McGuirk, Joseph P., Modi, Dipenkumar, Ramchandren, Radhakrishnan, Romancik, Jason, Cohen, Jonathon B., Frigault, Matthew J., Chen, Yi-Bin, Serritella, Anthony V., Kline, Justine, Ansell, Stephen, Nathan, Sunita, Rahimian, Maryam, Joyce, Robin M., Shah, Mansi, David, Kevin A., Park, Steven, Beaven, Anne W., Habib, Alma, Bachanova, Veronika, Nakhoda, Shazia, Khan, Nadia, Lynch, Ryan C., Smith, Stephen D., Ho, Vincent T., LaCasce, Ann, Armand, Philippe, Herrera, Alex F.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Hematology 2021
Konular:
Lymphoid Neoplasia
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7993097/
https://ncbi.nlm.nih.gov/pubmed/33710337
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020003556
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller